Qianjiang Yongan Pharmaceutical Co., Ltd.
Simbolis: 002365.SZ
SHZ
8.18
CNYRinkos kaina šiandien
1775.1724
P/E santykis
656.8138
PEG koeficientas
2.41B
MRK kapitalizacija
- 0.01%
DIV pajamingumas
Qianjiang Yongan Pharmaceutical Co., Ltd. (002365-SZ) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 3696.04 | 956.5 | 832.2 | 547.5 | ||||||||||||||||||
balance-sheet.row.short-term-investments | 2581.9 | 630.4 | 557.5 | 454 | ||||||||||||||||||
balance-sheet.row.net-receivables | 794.98 | 178.4 | 203.1 | 367.8 | ||||||||||||||||||
balance-sheet.row.inventory | 310.95 | 69.9 | 149.6 | 145.8 | ||||||||||||||||||
balance-sheet.row.other-current-assets | 21.25 | 8.8 | 10.4 | 4.8 | ||||||||||||||||||
balance-sheet.row.total-current-assets | 4823.23 | 1213.6 | 1195.3 | 1065.9 | ||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 3948.37 | 970.9 | 1023.5 | 989.3 | ||||||||||||||||||
balance-sheet.row.goodwill | 18.57 | 0.5 | 8.8 | 8.8 | ||||||||||||||||||
balance-sheet.row.intangible-assets | 331.84 | 82.4 | 84.5 | 87.9 | ||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 350.41 | 82.9 | 93.3 | 96.7 | ||||||||||||||||||
balance-sheet.row.long-term-investments | -926.92 | 68.3 | -476.1 | -338.8 | ||||||||||||||||||
balance-sheet.row.tax-assets | 40.83 | 11.3 | 9.7 | 9.9 | ||||||||||||||||||
balance-sheet.row.other-non-current-assets | 1311.93 | 0.1 | 578.5 | 462.9 | ||||||||||||||||||
balance-sheet.row.total-non-current-assets | 4724.61 | 1133.5 | 1228.8 | 1220 | ||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-assets | 9547.85 | 2347.1 | 2424.2 | 2285.9 | ||||||||||||||||||
balance-sheet.row.account-payables | 542.02 | 128.8 | 162.8 | 114.9 | ||||||||||||||||||
balance-sheet.row.short-term-debt | 93.03 | 47.3 | 40 | 20.4 | ||||||||||||||||||
balance-sheet.row.tax-payables | 56.99 | 7.8 | 4.9 | 5.5 | ||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 0 | ||||||||||||||||||
Deferred Revenue Non Current | 35.42 | 8.5 | 11.3 | 13.1 | ||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 114.65 | - | - | - | ||||||||||||||||||
balance-sheet.row.other-current-liab | 161.86 | 65.6 | 70.6 | 78.5 | ||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 141.57 | 33.1 | 36 | 35.6 | ||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-liab | 1163.17 | 290.3 | 321.2 | 328.9 | ||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.common-stock | 1178.73 | 294.7 | 294.7 | 294.7 | ||||||||||||||||||
balance-sheet.row.retained-earnings | 3406.61 | 812.7 | 854.5 | 728.2 | ||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 2079.42 | 163.8 | 155.4 | 130.9 | ||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1425.56 | 712.8 | 712.8 | 712.2 | ||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 8090.32 | 1983.9 | 2017.4 | 1865.9 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 9547.85 | 2347.1 | 2424.2 | 2285.9 | ||||||||||||||||||
balance-sheet.row.minority-interest | 285.85 | 64.4 | 85.6 | 91.1 | ||||||||||||||||||
balance-sheet.row.total-equity | 8376.17 | 2048.3 | 2103 | 1957 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 9547.85 | - | - | - | ||||||||||||||||||
Total Investments | 1654.98 | 698.7 | 81.4 | 115.2 | ||||||||||||||||||
balance-sheet.row.total-debt | 93.03 | 47.3 | 40 | 20.4 | ||||||||||||||||||
balance-sheet.row.net-debt | -1021.1 | -278.9 | -234.7 | -73.1 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 1.38 | -12.3 | 132.7 | 119 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0.09 | 135.2 | 123.6 | 116 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 6.8 | 2.4 | -3.8 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | -176.9 | 0.9 | 12.4 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | 106.58 | 93.5 | 99.1 | -152.4 | ||||||||||||||||||
cash-flows.row.account-receivables | 18.85 | 18.9 | 163.2 | -172.1 | ||||||||||||||||||
cash-flows.row.inventory | 87.73 | 87.7 | -10 | -63.7 | ||||||||||||||||||
cash-flows.row.account-payables | 0 | -13.1 | -56.5 | 87.2 | ||||||||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 2.4 | -3.8 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 71.81 | 197.9 | 28.5 | 10.7 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 179.87 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -119.09 | -120.7 | -149.1 | -63 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 0.87 | 1 | 0.4 | -35.9 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | -1350.13 | -1484.2 | -1110.7 | -823.2 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 1299.19 | 1392.7 | 1029 | 943.5 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 22.57 | 45.2 | 0 | 0.5 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -123.95 | -166 | -230.4 | 21.8 | ||||||||||||||||||
cash-flows.row.debt-repayment | -10.6 | -30 | -40 | -132.3 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | -44.62 | -29.5 | -1.6 | -30.7 | ||||||||||||||||||
cash-flows.row.other-financing-activites | -2.27 | -6.3 | 59.4 | 23.8 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -41.19 | -65.8 | 17.8 | -139.2 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 10.45 | 7.1 | 6.5 | -1.1 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | 9.69 | 51.5 | 181.2 | -16.7 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 1070.94 | 326.2 | 274.7 | 93.5 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1061.25 | 274.7 | 93.5 | 110.2 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | 179.87 | 244.3 | 387.3 | 101.8 | ||||||||||||||||||
cash-flows.row.capital-expenditure | -119.09 | -120.7 | -149.1 | -63 | ||||||||||||||||||
cash-flows.row.free-cash-flow | 60.78 | 123.5 | 238.2 | 38.8 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 852.45 | 962.8 | 1462.4 | 1565.4 | ||||||||||||||||||
income-statement-row.row.cost-of-revenue | 643.48 | 733.5 | 980.8 | 1206.9 | ||||||||||||||||||
income-statement-row.row.gross-profit | 208.97 | 229.3 | 481.7 | 358.5 | ||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.research-development | 41.02 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-general-administrative | 73.14 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 18.03 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-expenses | -94.9 | -1.2 | 66.2 | 69.7 | ||||||||||||||||||
income-statement-row.row.operating-expenses | 280.6 | 205 | 320.3 | 228.6 | ||||||||||||||||||
income-statement-row.row.cost-and-expenses | 924.08 | 938.5 | 1301.1 | 1435.4 | ||||||||||||||||||
income-statement-row.row.interest-income | 1.56 | 1.9 | 0.3 | 0.2 | ||||||||||||||||||
income-statement-row.row.interest-expense | 0.4 | 0.4 | 0.7 | 2.4 | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 18.03 | - | - | - | ||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 66.41 | -20.9 | 0.7 | -1.8 | ||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-operating-expenses | -94.9 | -1.2 | 66.2 | 69.7 | ||||||||||||||||||
income-statement-row.row.total-operating-expenses | 66.41 | -20.9 | 0.7 | -1.8 | ||||||||||||||||||
income-statement-row.row.interest-expense | 0.4 | 0.4 | 0.7 | 2.4 | ||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 59.89 | 135.2 | 167.1 | 132.3 | ||||||||||||||||||
income-statement-row.row.ebitda-caps | -1.6 | - | - | - | ||||||||||||||||||
income-statement-row.row.operating-income | -43.84 | 24.3 | 152.4 | 131.7 | ||||||||||||||||||
income-statement-row.row.income-before-tax | 22.57 | 3.4 | 153.1 | 129.9 | ||||||||||||||||||
income-statement-row.row.income-tax-expense | 38.46 | 34.5 | 20.3 | 10.8 | ||||||||||||||||||
income-statement-row.row.net-income | 1.38 | -12.3 | 140.3 | 111.4 |
Dažnai užduodami klausimai
Kas yra Qianjiang Yongan Pharmaceutical Co., Ltd. (002365.SZ) bendras turtas?
Qianjiang Yongan Pharmaceutical Co., Ltd. (002365.SZ) bendras turtas yra 2347138093.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra 360799673.000.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.245.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra 0.206.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.002.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra -0.051.
Kas yra Qianjiang Yongan Pharmaceutical Co., Ltd. (002365.SZ) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra -12312563.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 47305897.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 205002116.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 244645727.000.